Identification of a novel NPM1 mutation in acute myeloid leukemia
Open Access
- 4 October 2023
- journal article
- letter
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 12 (1) , 1-5
Abstract
Nucleophosmin (NPM1) is a widely expressed nucleocytoplasmic shuttling protein with prominent nucleolar localization. It is estimated that 25–35% of adult patients with acute myeloid leukemia (AML) carryNPM1mutations. The classicNPM1type A mutation occurs in exon 12, which accounts for 75–80% of adult patients withNPM1-mutated AML. It produces an additional leucine and valine-rich nuclear export signal (NES) at the C-terminus, and causes aberrant cytoplasmic dislocation of NPM1 protein. Notably, emerging evidence indicates that besides the classic type A mutation, rare mutants occurring in other exons may also lead to the imbalance of the nucleocytoplasmic shuttle of NPM1. Identification of novel non-type A mutants is crucial for the diagnosis, prognosis, risk stratification and disease monitoring of potential target populations. Here we reported a novelNPM1mutation in exon 5 identified from a de novo AML patient. Similar to the classic type A mutation, the exon 5 mutation had the NPM1 mutant bound to exportin-1 and directed the mutant into the cytoplasm by generating an additional NES sequence, resulting in aberrant cytoplasmic dislocation of NPM1 protein, which could be reversed by exportin-1 inhibitor leptomycin B. Our findings strongly support that besides the exon 12 mutation, the exon 5 mutant is anotherNPM1“born to be exported” mutant critical for leukemogenesis. Therefore, similar to the classic type A mutation, the identification of our novelNPM1mutation is beneficial for clinical laboratory diagnosis, genetic risk assessment and MRD monitoring.Keywords
Funding Information
- 2023 Science and Technology Innovation Plan of Shanghai Science and Technology Commission (23141902700)
- the Fundamental Research Funds for the Central Universities (226-2022-00003)
- Natural Science Foundation of Zhejiang Province, China (Y23H080018)
- Key Research and Development Program of Zhejiang Province, China (2022C03005)
This publication has 13 references indexed in Scilit:
- Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 yearsLeukemia, 2020
- AML through the prism of molecular geneticsBritish Journal of Haematology, 2019
- A novel type of NPM1 mutation characterized by multiple internal tandem repeats in a case of cytogenetically normal acute myeloid leukemiaHaematologica, 2018
- Biological and clinical consequences of NPM1 mutations in AMLLeukemia, 2017
- Two novel NPM1 mutations in a therapy‐responder AML patientHematological Oncology, 2009
- Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtypeInternational Journal of Hematology, 2009
- A new type of NPM1 gene mutation in AML leading to a C-terminal truncated proteinLeukemia, 2007
- Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutationLeukemia, 2007
- Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signalOncogene, 2006
- Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significanceBlood, 2005